Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAVrh.10CUCLN2 Gene Therapy for LINCL (Batten Disease)
NCT01414985Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Apr 2010
- Primary completion
- Nov 2015
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of AAVrh.10CUhCLN2 in late infantile neuronal ceroid lipofuscinosis (LINCL), sponsored by Weill Cornell Medicine. Started Apr 2010; status: completed.
02
Drugs
AAVrh.10CUhCLN2
03
Conditions
late infantile neuronal ceroid lipofuscinosis (LINCL)
Beyond the preview
Go deeper on NCT01414985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01414985.